Cargando…

Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

Developmental pharmacology describes the impact of maturation on drug disposition (pharmacokinetics, PK) and drug effects (pharmacodynamics, PD) throughout the paediatric age range. This paper, written by a multidisciplinary group of experts, summarizes current knowledge, and provides suggestions to...

Descripción completa

Detalles Bibliográficos
Autores principales: Smits, Anne, Annaert, Pieter, Cavallaro, Giacomo, De Cock, Pieter A. J. G., de Wildt, Saskia N., Kindblom, Jenny M., Lagler, Florian B., Moreno, Carmen, Pokorna, Paula, Schreuder, Michiel F., Standing, Joseph F., Turner, Mark A., Vitiello, Benedetto, Zhao, Wei, Weingberg, Annelie‐Martina, Willmann, Raffaella, van den Anker, John, Allegaert, Karel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787161/
https://www.ncbi.nlm.nih.gov/pubmed/34180088
http://dx.doi.org/10.1111/bcp.14958
_version_ 1784858450839207936
author Smits, Anne
Annaert, Pieter
Cavallaro, Giacomo
De Cock, Pieter A. J. G.
de Wildt, Saskia N.
Kindblom, Jenny M.
Lagler, Florian B.
Moreno, Carmen
Pokorna, Paula
Schreuder, Michiel F.
Standing, Joseph F.
Turner, Mark A.
Vitiello, Benedetto
Zhao, Wei
Weingberg, Annelie‐Martina
Willmann, Raffaella
van den Anker, John
Allegaert, Karel
author_facet Smits, Anne
Annaert, Pieter
Cavallaro, Giacomo
De Cock, Pieter A. J. G.
de Wildt, Saskia N.
Kindblom, Jenny M.
Lagler, Florian B.
Moreno, Carmen
Pokorna, Paula
Schreuder, Michiel F.
Standing, Joseph F.
Turner, Mark A.
Vitiello, Benedetto
Zhao, Wei
Weingberg, Annelie‐Martina
Willmann, Raffaella
van den Anker, John
Allegaert, Karel
author_sort Smits, Anne
collection PubMed
description Developmental pharmacology describes the impact of maturation on drug disposition (pharmacokinetics, PK) and drug effects (pharmacodynamics, PD) throughout the paediatric age range. This paper, written by a multidisciplinary group of experts, summarizes current knowledge, and provides suggestions to pharmaceutical companies, regulatory agencies and academicians on how to incorporate the latest knowledge regarding developmental pharmacology and innovative techniques into neonatal and paediatric drug development. Biological aspects of drug absorption, distribution, metabolism and excretion throughout development are summarized. Although this area made enormous progress during the last two decades, remaining knowledge gaps were identified. Minimal risk and burden designs allow for optimally informative but minimally invasive PK sampling, while concomitant profiling of drug metabolites may provide additional insight in the unique PK behaviour in children. Furthermore, developmental PD needs to be considered during drug development, which is illustrated by disease‐ and/or target organ‐specific examples. Identifying and testing PD targets and effects in special populations, and application of age‐ and/or population‐specific assessment tools are discussed. Drug development plans also need to incorporate innovative techniques such as preclinical models to study therapeutic strategies, and shift from sequential enrolment of subgroups, to more rational designs. To stimulate appropriate research plans, illustrations of specific PK/PD‐related as well as drug safety‐related challenges during drug development are provided. The suggestions made in this joint paper of the Innovative Medicines Initiative conect4children Expert group on Developmental Pharmacology and the European Society for Developmental, Perinatal and Paediatric Pharmacology, should facilitate all those involved in drug development.
format Online
Article
Text
id pubmed-9787161
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97871612022-12-27 Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper Smits, Anne Annaert, Pieter Cavallaro, Giacomo De Cock, Pieter A. J. G. de Wildt, Saskia N. Kindblom, Jenny M. Lagler, Florian B. Moreno, Carmen Pokorna, Paula Schreuder, Michiel F. Standing, Joseph F. Turner, Mark A. Vitiello, Benedetto Zhao, Wei Weingberg, Annelie‐Martina Willmann, Raffaella van den Anker, John Allegaert, Karel Br J Clin Pharmacol Article Developmental pharmacology describes the impact of maturation on drug disposition (pharmacokinetics, PK) and drug effects (pharmacodynamics, PD) throughout the paediatric age range. This paper, written by a multidisciplinary group of experts, summarizes current knowledge, and provides suggestions to pharmaceutical companies, regulatory agencies and academicians on how to incorporate the latest knowledge regarding developmental pharmacology and innovative techniques into neonatal and paediatric drug development. Biological aspects of drug absorption, distribution, metabolism and excretion throughout development are summarized. Although this area made enormous progress during the last two decades, remaining knowledge gaps were identified. Minimal risk and burden designs allow for optimally informative but minimally invasive PK sampling, while concomitant profiling of drug metabolites may provide additional insight in the unique PK behaviour in children. Furthermore, developmental PD needs to be considered during drug development, which is illustrated by disease‐ and/or target organ‐specific examples. Identifying and testing PD targets and effects in special populations, and application of age‐ and/or population‐specific assessment tools are discussed. Drug development plans also need to incorporate innovative techniques such as preclinical models to study therapeutic strategies, and shift from sequential enrolment of subgroups, to more rational designs. To stimulate appropriate research plans, illustrations of specific PK/PD‐related as well as drug safety‐related challenges during drug development are provided. The suggestions made in this joint paper of the Innovative Medicines Initiative conect4children Expert group on Developmental Pharmacology and the European Society for Developmental, Perinatal and Paediatric Pharmacology, should facilitate all those involved in drug development. John Wiley and Sons Inc. 2021-07-23 2022-12 /pmc/articles/PMC9787161/ /pubmed/34180088 http://dx.doi.org/10.1111/bcp.14958 Text en © 2021 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Article
Smits, Anne
Annaert, Pieter
Cavallaro, Giacomo
De Cock, Pieter A. J. G.
de Wildt, Saskia N.
Kindblom, Jenny M.
Lagler, Florian B.
Moreno, Carmen
Pokorna, Paula
Schreuder, Michiel F.
Standing, Joseph F.
Turner, Mark A.
Vitiello, Benedetto
Zhao, Wei
Weingberg, Annelie‐Martina
Willmann, Raffaella
van den Anker, John
Allegaert, Karel
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper
title Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper
title_full Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper
title_fullStr Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper
title_full_unstemmed Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper
title_short Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper
title_sort current knowledge, challenges and innovations in developmental pharmacology: a combined conect4children expert group and european society for developmental, perinatal and paediatric pharmacology white paper
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787161/
https://www.ncbi.nlm.nih.gov/pubmed/34180088
http://dx.doi.org/10.1111/bcp.14958
work_keys_str_mv AT smitsanne currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT annaertpieter currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT cavallarogiacomo currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT decockpieterajg currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT dewildtsaskian currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT kindblomjennym currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT laglerflorianb currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT morenocarmen currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT pokornapaula currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT schreudermichielf currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT standingjosephf currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT turnermarka currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT vitiellobenedetto currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT zhaowei currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT weingberganneliemartina currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT willmannraffaella currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT vandenankerjohn currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper
AT allegaertkarel currentknowledgechallengesandinnovationsindevelopmentalpharmacologyacombinedconect4childrenexpertgroupandeuropeansocietyfordevelopmentalperinatalandpaediatricpharmacologywhitepaper